TY - JOUR
T1 - Recurrent/metastatic squamous cell carcinoma of the head and neck
T2 - A big and intriguing challenge which may be resolved by integrated treatments combining locoregional and systemic therapies
AU - Ionna, Franco
AU - Bossi, Paolo
AU - Guida, Agostino
AU - Alberti, Andrea
AU - Muto, Paolo
AU - Salzano, Giovanni
AU - Ottaiano, Alessandro
AU - Maglitto, Fabio
AU - Leopardo, Davide
AU - De Felice, Marco
AU - Longo, Francesco
AU - Tafuto, Salvatore
AU - Scarpati, Giuseppina Della Vittoria
AU - Perri, Francesco
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/5/2
Y1 - 2021/5/2
N2 - Squamous cell carcinoma of the head and neck (SCCHN) is a complex group of malignan-cies, posing several challenges to treating physicians. Most patients are diagnosed with a locally advanced disease and treated with strategies integrating surgery, chemotherapy, and radiotherapy. About 50% of these patients will experience a recurrence of disease. Recurrent/metastatic SCCHN have poor prognosis with a median survival of about 12 months despite treatments. In the last years, the strategy to manage recurrent/metastatic SCCHN has profoundly evolved. Salvage treatments (surgery or re-irradiation) are commonly employed in patients suffering from locoregional recurrences and their role has gained more and more importance in the last years. Re-irradiation, using some particularly fractionating schedules, has the dual task of reducing the tumor mass and eliciting an immune response against cancer (abscopal effect). In this review, we will analyze the main systemic and/or locoregional strategies aimed at facing the recurrent/metastatic disease, underlining the enormous importance of the multidisciplinary approach in these types of patients.
AB - Squamous cell carcinoma of the head and neck (SCCHN) is a complex group of malignan-cies, posing several challenges to treating physicians. Most patients are diagnosed with a locally advanced disease and treated with strategies integrating surgery, chemotherapy, and radiotherapy. About 50% of these patients will experience a recurrence of disease. Recurrent/metastatic SCCHN have poor prognosis with a median survival of about 12 months despite treatments. In the last years, the strategy to manage recurrent/metastatic SCCHN has profoundly evolved. Salvage treatments (surgery or re-irradiation) are commonly employed in patients suffering from locoregional recurrences and their role has gained more and more importance in the last years. Re-irradiation, using some particularly fractionating schedules, has the dual task of reducing the tumor mass and eliciting an immune response against cancer (abscopal effect). In this review, we will analyze the main systemic and/or locoregional strategies aimed at facing the recurrent/metastatic disease, underlining the enormous importance of the multidisciplinary approach in these types of patients.
KW - Abscopal effect
KW - Immunotherapy
KW - Multidisciplinary team management
KW - Recurrent/metastatic
KW - Squamous cell carcinoma of the head and neck
UR - http://www.scopus.com/inward/record.url?scp=85105699596&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105699596&partnerID=8YFLogxK
U2 - 10.3390/cancers13102371
DO - 10.3390/cancers13102371
M3 - Review article
AN - SCOPUS:85105699596
VL - 13
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 10
M1 - 2371
ER -